[Comparative evaluation of biological availability and anti-arrhythmia effectiveness of Mexicard (mexiletine Polfa)].
In 16 healthy males bioavailability of Mexicord (Polfa) was studied, in comparison with mexiletine of foreign made. Bioavailability extent (EBA) of Mexicord was over 99% in comparison with a standard drug. Comparative study of antiarrhythmic activity and side effects was performed in 32 patients with frequent ventricular premalure beats and nearly in a half of them resistant to antiarrhythmic agents. Mexicord was effective in 47% of treated patients, and side effects (most often nausea) were observed in 28% of patients, but only in 1 case therapy withdrawal was necessary. Statistical study proved a lack of significant differences in antiarrhythmic effectiveness and side effects between Mexicord (Polfa) and a drug of foreign made.
Sadowski
Z
Z
Paczkowski
D
D
Markiewicz
M
M
Nartowicz
E
E
Koliński
P
P
Filipek
M
M
D000328:Adult; D000368:Aged; D001682:Biological Availability; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D005260:Female; D005860:Germany, West; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008875:Middle Aged; D011044:Poland; D013997:Time Factors
D008801:Mexiletine
Ocena porównawcza biodostepności i skuteczności antyarytmicznej Mexicordu (meksyletyny Polfa).